KZIA (Kazia Therapeutics) OCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KZIA Kazia Therapeutics Ltd KZIA
33 GF Score
Price $12.01
! 5 Warning Signs
View Full Analysis

What is Kazia Therapeutics OCF Margin %?

Kazia Therapeutics KZIA +0.08% 33 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates KZIA with a GF Score™ of 33/100. The stock has 5 warning signs investors should review. Among 961 Biotechnology companies, Kazia Therapeutics ranks worse than 97.19% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Kazia Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was $-6.34 Mil. Kazia Therapeutics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Kazia Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Kazia Therapeutics's current OCF Yield % is -5.09%.

The historical rank and industry rank for Kazia Therapeutics's OCF Margin % or its related term are showing as below:

KZIA' s OCF Margin % Range Over the Past 10 Years
Min: -32018.52   Med: -3854.69   Max: -60.01
Current: -35196.3

During the past 13 years, the highest OCF Margin % of Kazia Therapeutics was -60.01%. The lowest was -32018.52%. And the median was -3854.69%.

KZIA's OCF Margin % is ranked worse than
97.19% of 961 companies
in the Biotechnology industry
Industry Median: -67.62 vs KZIA: -35196.30

Kazia Therapeutics OCF Margin % Related Terms

Kazia Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Kazia Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kazia Therapeutics OCF Margin % Chart

Kazia Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.01 0.00 0.00 -415.00 -32,018.52

Kazia Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -140.57 0.00 -11,714.81 0.00

KZIA vs OKUR, TNYA, OTLK: OCF Margin % Comparison

For the Biotechnology subindustry, Kazia Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kazia Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's OCF Margin % falls into.


KZIA
33GF Score
Kazia Therapeutics Ltd KZIA
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kazia Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Kazia Therapeutics's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-8.645/0.027
=-32,018.52 %

Kazia Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-6.34/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Kazia Therapeutics (KZIA) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kazia Therapeutics and its competitors. According to the industry distribution chart, Kazia Therapeutics ranks #934 out of 961 companies in the Biotechnology industry, placing it in the top 97.2%.
Is Kazia Therapeutics' OCF Margin % too high?
Kazia Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Kazia Therapeutics ranks #934 out of 961 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kazia Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Kazia Therapeutics' OCF Margin % compare to OKUR and TNYA?
According to the Biotechnology industry distribution chart, Kazia Therapeutics ranks #934 out of 961 companies for OCF Margin %. This places Kazia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kazia Therapeutics and its competitors. Kazia Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kazia Therapeutics stock overvalued right now?
Kazia Therapeutics (KZIA) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Kazia Therapeutics' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kazia Therapeutics (KZIA), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kazia Therapeutics Business Description

Address 300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
33GF Score

Get the complete analysis for KZIA

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.01
Price